Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Want to cut your energy bills? Here’s how five experts are doing it 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
JERSEY CITY, N.J., March 07, 2017 -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the 29th Annual ROTH Conference at the Ritz Carlton Laguna Niguel in Dana Point on Tuesday, March 14, 2017 at 5:30 p.m. PT.
A live webcast will be available on the Investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Cammy Duong MacDougall Biomedical Communications Tel: 781.591.3443 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
